Abstract
IL-6 trans-signaling blockade inhibits chronic inflammation in human lamina propria1. Trans-signaling inhibition may have safety advantages over pan-IL-6 inhibitors (i.e. IL-6 or IL-6R antibodies) by preserving membrane IL-6R signaling. We evaluated the efficacy and safety of olamkicept, a soluble gp130-Fc fusion protein that inhibits trans-signaling by binding to the IL-6/ soluble IL-6R complex, for induction in active ulcerative colitis (UC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
